$ACT

Enact (ACT) Q2 2026 Earnings Call Transcript

Enact (ACT) reported Q2 2026 adjusted operating income of $177 million, or $1.26 per diluted share, up from $174 million, or $1.15, in Q2 2025. New insurance written rose 15% to $15 billion. FY2026 capital return guidance was raised to $550 million to $600 million. Management cited $274 billion insurance in force and 161% PMIERs sufficiency.

Original reporting
Published Aug 13, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 12:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Enact (ACT) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ACTBullishMed
01

Why it matters

Traders can update expectations for ACT’s 2026 capital returns and near-term credit risk trajectory based on the revised guidance and management’s explicit 2H26 delinquency outlook.

02

Market read

The transcript contains a concrete upward revision to FY2026 capital return guidance and a forward-looking warning about rising delinquencies in the second half, both of which can move valuation and risk pricing.

03

What to watch

Loss ratio rose to 14% from 10% a year ago and persistency fell to 80%, suggesting the underwriting/credit cycle may be turning even as capital returns increase.

Relevance 8/10Novelty 7/10Timing: post-market Aug. 12 call transcript, actionable for near-term positioning ahead of next earnings/credit updates

Background

Enact Holdings (ACT) reported Q2 2026 results and discussed credit performance, capital adequacy (PMIERs), and capital return plans on its earnings call transcript.

Company-level read

Ticker impact

$ACTBullishMedium confidence
Context

Enact raised FY2026 capital return guidance to $550 million to $600 million and reported Q2 metrics including a higher loss ratio and buybacks.

Expected impact

Likely supportive for the stock on capital return confidence, but expect volatility as delinquency and loss-ratio deterioration risk is explicitly flagged for the second half.

Evidence & confidence

The article provides specific, decision-relevant numbers (capital return range revision, buybacks, PMIERs sufficiency) and a forward-looking risk statement (2H26 delinquency rise), which can drive both valuation and risk-premium repricing.

Market effects

Reinforces that private mortgage insurers are balancing elevated rates and seasonal delinquency with capital flexibility, which can influence sector risk appetite.

Most relevant to US housing finance and mortgage credit risk sentiment.

Limited direct global linkage beyond broader credit and housing-finance risk pricing.

Counterpoint

The guidance raise may be more about capital timing and current PMIERs headroom than durable credit improvement, so the 2H26 delinquency warning could dominate later.

Key entities

  • Enact Holdings, Inc.

    Subject of the earnings call transcript, providing Q2 2026 operating and credit metrics plus revised FY2026 capital return guidance.

  • Rohit Gupta

    CEO who discussed underwriting innovation (ELLA) and market/pricing outlook for private mortgage insurance.

  • Dean Mitchell

    CFO who detailed credit metrics (delinquencies, loss ratio, reserve release) and warned delinquency rate is expected to rise in 2H26.

  • Daniel Kohl

    VP of Finance who opened the call and referenced the earnings materials released after market close.

Related articles

$ACTMed

JPMorgan downgrades Enact Holdings stock rating on valuation

JPMorgan downgraded Enact Holdings (ACT) to Underweight, lowering its price target to $44.00. The stock trades at $45.97, above the target and fair value estimates, suggesting overvaluation. JPMorgan cited premium valuation and mixed effects from higher interest rates. Enact reported Q2 2026 earnings beating estimates, with $1.26 EPS and $317.3M revenue. BTIG initiated coverage with a Neutral rating, noting expected ROE declines.

$LSTRMed

StoneX reiterates Hold on Landstar stock after insurance costs hit

StoneX kept a Hold rating on Landstar System (LSTR) after Q3 2026 earnings missed estimates due to higher insurance costs. EPS was $1.42, below StoneX's $1.61 estimate and consensus of $1.67. Revenue rose to $1.507B, slightly above forecasts. Analysts lowered price targets, citing cost concerns. LSTR trades at a P/E of 36.88 and is considered undervalued by InvestingPro.